The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.
Study Type
OBSERVATIONAL
Enrollment
793
Oral
Unnamed facility
Numakunai, Iwate, Japan
Unnamed facility
Aichi, Japan
Incidences of Adverse Drug Reactions
Time frame: Up to Week 52
Change from baseline in frequency of bowel movements
Frequency of bowel movements is recorded daily
Time frame: Baseline to Week 52
Change from baseline in form of stool
Classified based on Bristol Stool Form Scale
Time frame: Baseline to Week 52
Change from baseline in sensation of incomplete bowel evacuation
Assessment based on numerical rating scale
Time frame: Baseline to Week 52
Change from baseline in defecation urgency
Time frame: Baseline to Week 52
Change from baseline in abdominal pain or discomfort
Abdominal pain or discomfort assessed based on numerical rating scale
Time frame: Baseline to Week 52
Change from baseline in melena
Time frame: Baseline to Week 52
Overall improvement
Classified into the three scales (improved, no change or aggravated) or concluded as indeterminable.
Time frame: Up to Week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Akita, Japan
Unnamed facility
Chiba, Japan
Unnamed facility
Fukui, Japan
Unnamed facility
Fukuoka, Japan
Unnamed facility
Fukushima, Japan
Unnamed facility
Gifu, Japan
Unnamed facility
Gunma, Japan
Unnamed facility
Hiroshima, Japan
...and 24 more locations